Therapy for the treatment of disease
AssigneeTheravida, Inc.
InventorMehdi Paborji
Life of this patent
Estimating the term…
Abstract
Disclosed herein are pharmaceutical compositions comprising oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition.
Claims20
A pharmaceutical composition comprising a therapeutically effective amount of oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof,
- wherein the oxybutynin and pilocarpine are formulated such that the peak saliva flow time point for pilocarpine occurs at nearly the same time as the lowest saliva flow time point for oxybutynin.
A pharmaceutical composition comprising a dose of oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, in the range of between 1 mg to 30 mg, in combination with a dose of pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, in the range of between 1 mg to 30 mg,
- wherein the oxybutynin and pilocarpine are formulated such that the peak saliva flow time point for pilocarpine occurs at nearly the same time as the lowest saliva flow time point for oxybutynin.
A pharmaceutical composition comprising 5 mg of oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, in combination with 5 mg of pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof,
- wherein the oxybutynin and pilocarpine are formulated such that the peak saliva flow time point for pilocarpine occurs at nearly the same time as the lowest saliva flow time point for oxybutynin.
Dependencies are inferred from the claim text.